[Contribution of the european economic community to pulmonary research (author's transl)].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to F Lavenne.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Xamoterol is a partial beta-1 adrenergic agonist capable of stabilising the beta-1 receptor to 43% of their maximal activity. Xamoterol was administered to 10 patients with moderate ischaemic heart failure at an oral dose of 200 mg twice a day. After 3 months, there was an improvement in left ventricular function: 28% reduction in the end-diastolic pressure (p less than 0.01), 12% reduction in ventricular volume (p less than 0.05) with a marked increase in the inotropic state. The exercise tolerance was also increased (+ 30 watt; p less than 0.05) and several indices suggest an improvement in myocardial metabolism. In conclusion, xamoterol is a positive inotrope which does not present the phenomenon of tachyphylaxis during the prolonged administration.